



## Supplementary Material

### Synergistic effects of A-B-C type amphiphilic copolymer on reversal of drug resistance in MCF-7/ADR breast carcinoma



**Figure S1** Synthesis route of PELA54-CD.


**Abbreviations:**  $\beta$ -CD,  $\beta$ -cyclodextrin; PEG5000-CD, PEGylated  $\beta$ -CD derivants; PELA54, copolymer with a feed ratio of mPEG5000 to LA: 5/4; PELA54-CD, a linear amphiphilic copolymer by linking  $\beta$ -CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio;  $\text{Sn}(\text{Oct})_2$ , stannous octoate;  $\text{Et}_3\text{N}$ , triethylamine; CI-CD, carbonyldiimidazole activated  $\beta$ -CD.



**Figure S2** TEM micrographs of polymeric micelles.


**Notes:** (A) PELA54-CD. (B) PELA54. (C) PEG5000-CD. Bar=0.1 μm.

**Abbreviations:** PEG5000-CD, PEGylated β-CD derivants; PELA54, copolymer with a feed ratio of mPEG5000 to LA: 5/4; PELA54-CD, a linear amphiphilic copolymer by linking β-CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio; TEM, Transmission Electron Microscope.




**Figure S3** DSC curves of DOX·HCl, blank PELA54-CD micelles, physical mixture of DOX·HCl and blank PELA54-CD micelles, and lyophilized PELA54-CD/DOX micelles.

**Abbreviations:** DOX, doxorubicin; DOX·HCl, free doxorubicin hydrochloride; PELA54-CD, a linear amphiphilic copolymer by linking β-CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio; PELA54-CD/DOX, DOX-loaded micelles; DSC, differential scanning calorimetry.



**Figure S4** Evolution of powder X-ray diffraction patterns of DOX·HCl powder, PELA54-CD lyophilized powder, physical mixture of DOX·HCl and blank PELA54-CD and PELA54-CD/DOX lyophilized powder.


**Abbreviations:** DOX, doxorubicin; DOX·HCl, free doxorubicin hydrochloride; PELA54-CD, a linear amphiphilic copolymer by linking  $\beta$ -CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio; PELA54-CD/DOX, DOX-loaded micelles; XRD, X Ray diffraction.



**Figure S5** Percentage of DOX-induced apoptosis in MCF-7/ADR cells detected by flow cytometry.

**Notes:** Cells were treated with DOX·HCl solution or in DOX-loaded micelles containing total DOX concentration of 2  $\mu\text{g}/\text{mL}$  for 48 h. The histogram shows the percentage of apoptosis represented as mean  $\pm$  S.D. ( $n=3$ ), statistical significance ( $p < 0.01$ ) was evaluated by using SPSS software when compared with DOX·HCl group.


**Abbreviations:** DOX·HCl, free doxorubicin hydrochloride; PELA54-CD/DOX, DOX-loaded micelles; PELA54/DOX, DOX-loaded micelles; PEG5000-CD/DOX, DOX-loaded cyclodextrin complex;  $\beta$ -CD/DOX, cyclodextrin-doxorubicin inclusion compound; Annexin-V FITC/PI, fluorescent dye used in flow cytometry.



**Figure S6** The cellular accumulation of Rh123 in MCF-7/ADR cells in the presence of different polymers.

**Notes:** (A) PELA54-CD. (B) PELA54. (C) PEG5000-CD. (D) β-CD. The results are represented as mean ± S.D. from three independent experiments (n=3).


**Abbreviations:** β-CD, β-cyclodextrin; PEG5000-CD, PEGylated β-CD derivants; PELA54, copolymer with a feed ratio of mPEG5000 to LA: 5/4; PELA54-CD, a linear amphiphilic copolymer by linking β-CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio; Rh123, Rhodamine 123.



**Figure S7** Cellular uptake of DOX in MCF-7/ADR cells in the presence of one of the endocytosis inhibitors (chlorpromazine, nystatin or amiloride) and PELA-CD/DOX with 10 μg/mL DOX concentration for 2 h at 37 °C.

**Notes:** The results are represented as mean ± SD (n=3), statistical significance (p < 0.05) was evaluated by using SPSS software when compared with control.



**Abbreviations:** PELA54-CD/DOX, DOX-loaded micelles; DOX, doxorubicin.



**Figure S8** P-gp expression in MCF-7 cells and MCF-7/ADR cells treated with different polymers.

**Notes:** (A) the untreated MCF-7 cells. (B) the untreated MCF-7/ADR cells. (C-F) MCF-7/ADR cells treated with different micelles (PELA54-CD, PELA54, PEG5000-CD,  $\beta$ -CD) at 50  $\mu\text{g}/\text{mL}$  for 24 h. P-gp expression was determined by flow cytometry using R-PE-conjugated mouse anti-human monoclonal antibody against P-gp. The percentage of area in the right frame indicated the relative quantity of P-gp expression.

**Abbreviations:**  $\beta$ -CD,  $\beta$ -cyclodextrin; PEG5000-CD, PEGylated  $\beta$ -CD derivants; PELA54, copolymer with a feed ratio of mPEG5000 to LA: 5/4; PELA54-CD, a linear amphiphilic copolymer by linking  $\beta$ -CD at the end of hydrophobic block of PEGylated poly(D,L-lactide) at 1:1 mole ratio; P-gp, P-glycoprotein.



**Figure S9** Zebrafish xenografts by microinjection of MCF-7/ADR cells without fluorescence labeling.

**Notes:** (A) The green area represent of tumor cells, red fluorescence belongs to natural fluorescence of DOX (20 ng of PELA54-CD/DOX or DOX·HCl was microinjected into the yolk sac 24 h after xenografts of MCF-7/ADR cells). **Scale bar=100  $\mu$ m.** (B) Fluorescence of CM-Dil-labeled tumor cell and autofluorescence of DOX in zebrafish, which showed that fluorescence signal of CM-Dil were not interferenced by the natural fluorescence of DOX.

**Abbreviations:** DOX, doxorubicin; DOX·HCl, free doxorubicin hydrochloride; PELA54-CD/DOX, DOX-loaded micelles.